Virtual park cycling could slow muscle decline in children
NCT ID NCT07580365
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study tests whether cycling while using a virtual park app can slow the loss of motor function in children and teens with neuromuscular diseases like muscular dystrophy. Twenty-two participants will first receive standard care for 3 months, then use the virtual park bike 3 times a week for another 3 months. The goal is to see if the dual-task training improves movement, thinking, and engagement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dual-task cycling with VirtualPark software
- What this could lead to
- If it works, this could provide a fun, engaging way to help children with neuromuscular diseases maintain their motor function longer.
- What could go wrong
- This is a very small early trial with only 22 participants, so results may not apply widely. The intervention is non-invasive but may not slow decline significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL MYOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Don Gnocchi - Centro "S. Maria al Mare"
SUSPENDEDSalerno, SA, 84131, Italy
-
IRCCS E. Medea - La Nostra Famiglia
RECRUITINGBosisio Parini, LC, 23849, Italy
-
IRCCS Fondazione Mondino
RECRUITINGPavia, PV, 27100, Italy
-
IRCCS Fondazione Stella Maris
RECRUITINGPisa, PI, 56128, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to sharpen tools for tracking becker muscular dystrophy
- New drug could help boys with duchenne walk and move longer
- Data dive: 2500 Patients' records could speed up duchenne treatment advances
- New hope for FSHD: Long-Term drug safety trial underway
- Hope for duchenne: new drug targets rare gene mutation in phase 3 trial
- Global registry aims to speed up duchenne research by linking patients to studies